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Objective. Based on cell kinetics, post-operative adjuvant chemotherapy should 29 
eradicate microscopic cancer cells. The appropriate timing of chemotherapy following 30 
amputation for osteosarcoma is unknown. We retrospectively examined the time 31 
interval (TI) between amputation and chemotherapy initiation in dogs with appendicular 32 
osteosarcoma without distant metastases, and whether TI played any role in outcome. 33 
Aims of the analysis were to evaluate whether an optimum TI for initiating adjuvant 34 
chemotherapy and/or a TI after which treatment benefit became negligible could be 35 
identified. 36 
Animals. 168 client-owned dogs. 37 
Procedures. Dogs were classified into 8 groups based on whether they received 38 
chemotherapy within 3, 5, 7, 10, 15, 20, 30 or >30 days after surgery. Univariate and 39 
multivariate analyses were performed to determine the prognostic factors of progression 40 
and survival outcomes. 41 
Results. The median TI between surgery and chemotherapy was 14 days (range, 1-210). 42 
Median time to progression of dogs receiving chemotherapy within 5 days [375 43 
(95%CI, 162-588)] was significantly longer than that of dogs treated after 5 days [202 44 
(95%CI, 146-257)]; P = 0.005]. Median overall survival of dogs receiving 45 
chemotherapy within 5 days [445 (95%CI, 345-545)] was significantly longer than that 46 
of dogs treated after 5 days [239 (95%CI, 186-291)]; P = 0.003]. The survival benefit of 47 
chemotherapy was lost with a delay of 4 weeks from amputation. 48 
Conclusions and clinical relevance. The present analysis showed a significant 49 
association with survival for earlier delivery of adjuvant chemotherapy. These results 50 
suggest that the timing of chemotherapy may be an important prognostic variable. 51 
 52 
 3 
Abbreviation list 53 
ALP: alkaline phosphatase 54 
CI: confidence interval 55 
OS: overall survival 56 
TBCT: total body computed tomography 57 
TI: time interval 58 
TNM tumor node metastasis 59 





Canine appendicular osteosarcoma is an aggressive malignancy with a guarded 65 
prognosis. Although therapeutic options continue to evolve, limb amputation or limb 66 
sparing followed by systemic chemotherapy remains the only potentially curative option 67 
for the disease, yet only 20% of dogs survive >2 years after diagnosis.1  68 
While only 10% of dogs are diagnosed with clinically evident distant metastasis at 69 
admission, approximately 90% have occult micrometastases by the time osteosarcoma 70 
is diagnosed.2,3 Given the rapid growth behavior and metastatic potential of 71 
osteosarcoma, adjuvant platinum chemotherapy, with or without alternating 72 
doxorubicin, has become the standard of care in dogs undergoing limb amputation, as 73 
this has provided a survival benefit in multiple studies.3  74 
The concept that perioperative delivery of chemotherapy may improve outcome is not 75 
new. A murine study suggested that the temporal relationship between surgery and 76 
chemotherapy was an important variable in determining outcome in osteosarcoma, with 77 
mice treated at the time of surgery experiencing an enhancement of drug effect.4 The 78 
 4 
biological rationale behind this phenomenon is most likely due to the recruitment of 79 
resting metastatic cells into the cell cycle once the primary tumor has been removed.5,6 80 
In human osteosarcoma patients, early initiation of chemotherapy following surgery has 81 
provided a survival benefit, as data suggest a worse outcome when medical treatment is 82 
delayed.7,8 83 
In dogs there is no clear evidence that TI between surgery and initiation of 84 
chemotherapy is associated with better survival. Adjuvant chemotherapy is commonly 85 
started two weeks after surgery, to allow maximum patient recovery.1,9,10 A study 86 
comparing survival time for dogs starting chemotherapy 2 and 10 days after surgery 87 
suggested no benefit to early initiation of adjuvant therapy.11 It may be possible that the 88 
optimal window for identifying survival benefits was missed in that study.  89 
We sought to examine the impact of TI on outcome by a retrospective analysis of a 90 
large cohort of dogs with appendicular osteosarcoma. The purposes of the analysis were 91 
to evaluate whether an optimal TI could be identified and whether there is a TI after 92 
which the benefit of adjuvant chemotherapy is lost. It was hypothesized that early 93 
delivery of adjuvant chemotherapy improves outcome. 94 
 95 
 96 
Material and methods 97 
 98 
The current study was designed by the Italian Society of Veterinary Oncology 99 
(SIONCOV). Medical data of dogs that underwent limb amputation followed by 100 
chemotherapy were retrospectively analyzed. Medical records and reported data were 101 
checked and reviewed in each center. 102 
Dogs were included if, in accordance with the current TNM staging system, they had a 103 
histologically-confirmed appendicular osteosarcoma; had no evidence of distant 104 
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metastases prior to amputation; had a body weight >15 kg; underwent tumor excision; 105 
received at least 2 cycles of adjuvant dose-intense chemotherapy; and had complete 106 
follow-up data. 107 
Dogs were excluded if the osteosarcoma involved the metacarpus, metatarsus or 108 
phalanges due to the presumed better prognosis.12 Dogs with scapula osteosarcoma 109 
were also excluded because of the different surgical procedure (partial or total 110 
scapulectomy instead of limb amputation). 111 
All owners gave their written informed consent to use of the medical records of their 112 
dogs. 113 
 114 
Staging work-up and follow-up 115 
To be included in the analysis, dogs had to be staged by means of TBCT or 3-view 116 
thoracic radiographs and abdominal ultrasound, and cytological and/or 117 
histopathological evaluation of the regional lymph node. If available, hematology and 118 
serum biochemistry results at admission were also recorded. Routine monitoring for 119 
pulmonary metastasis with thoracic radiographs occurred every 2-3 cycles of 120 
chemotherapy, unless clinical signs suspicious for metastasis were present, in which 121 
case imaging was carried out sooner. Follow-up abdominal ultrasound occurred 122 
according to each clinician’s and owner’s preference. Once chemotherapy was 123 
completed, dogs were followed-up every 2-3 months. 124 
 125 
Statistical analysis 126 
TTP was calculated as the interval between amputation and the date of first-documented 127 
disease progression (local recurrence and/ or metastasis); dogs with no disease 128 
progression at data-analysis closure or death were censored. OS was calculated as the 129 
interval between amputation and death from any cause. Dogs alive at data-analysis 130 
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closure were censored. Survival plots were generated according to the Kaplan-Meier 131 
product limit method and compared with the log-rank test. Survival estimates were 132 
presented as medians with the corresponding 95%CI. The influence of potentially 133 
prognostic variables, including sex, age (<5 years vs >5 years)13, weight (median used 134 
as cutoff value), symptom duration prior to diagnosis (median used as cutoff value), site 135 
of osteosarcoma (proximal humerus vs others), ALP level (normal vs increased), 136 
monocyte count (normal vs increased), lymphocyte count (normal vs increased), type of 137 
imaging (thoracic radiographs/ TBCT), presence of lymph node metastasis (yes vs no), 138 
chemotherapy-related toxicity according to VCOG criteria14 (yes vs. no and grades 3-4 139 
vs. others), surgical complications (none/minor vs major) was investigated with 140 
univariable Cox's regression analysis.  141 
Minor complications were defined as surgery‐related events requiring only minor 142 
invasive procedures (such as drainage of wounds infection or seroma, and wound 143 
management in case of suture dehiscence or superficial infection), whereas major 144 
complications referred to adverse events requiring reoperation or resulting in failure of 145 
one or more organ systems. 146 
Factors with a P value < 0.1 on univariable analysis were further tested for 147 
independence in a multivariable Cox proportional hazard model. 148 
TI between amputation and the first day of chemotherapy was analyzed as a categorical 149 
variable and as a continuous variable. For the categorical data, dogs were classified into 150 
8 groups based on whether they received chemotherapy within 3, 5, 7, 10, 15, 20, 30 151 
days or >30 days after surgery. The risk of tumor progression and mortality of the dogs 152 
within each group was then compared with the remaining dogs (e.g. ≤ 3 days vs. > 3 153 
days; ≤ 5 days vs. > 5 days, etc.) with Cox’s regression analysis and the TI with the 154 
highest significant hazard ratio was selected. For the continuous data, a Mann-Whitney 155 
U test was applied to assess TI differences between dogs alive 1 year following surgery 156 
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and those deceased earlier. 157 
The distribution of possible prognostic outcome variables between dogs treated within 158 
the selected optimal TI and the remaining dogs was compared with Fisher's exact 159 
test/χ2test.  160 
Analyses were carried out using a commercial software programa; the significance level 161 






From January 2012 to December 2019, 168 dogs with appendicular osteosarcoma that 168 
met the inclusion criteria and that were treated in 9 European oncology centers were 169 
included in the database. 170 
There were 134 (79.8%) purebred dogs and 34 (20.2%) crossbred dogs. In order of 171 
prevalence, Rottweiler (n=27; 16.1%), German shepherd (n=13; 7.7%), boxers (n=11; 172 
6.5%), greyhound (n=7; 4.2%), great Dane (n=5; 3%), and Schnauzer (n=5; 3%) were 173 
the most commonly represented pure breeds. All other breeds represented less than 3% 174 
each. There were 86 (51.2%) male dogs (of which 36 were castrated) and 82 (48.8%) 175 
females (of which 52 were spayed). Thirty-four dogs (20.2%) were less than 5 years of 176 
age, while 134 (79.8%) were older than 10. Median age was 8 years (range, 1 to 14 177 
years) and median weight was 32.2 kg (range, 16.2 to 75 kg). 178 
All dogs were lame at the time of presentation; median symptom duration was 28 days 179 
(range, 2 to 120 days). Osteosarcoma location was: distal radius (n=44; 26.2%), 180 
proximal humerus (n=38; 22.6%), distal femur (n=33; 19.6%), distal tibia (n=22; 181 
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13.1%), proximal femur (n=13; 7.7%), proximal tibia (n=11; 6.5%), and distal ulna 182 
(n=7; 4.2%). 183 
Nine diagnostic laboratories provided services to the multiple institutions and veterinary 184 
hospitals participating in the study, so several reference intervals were used. Total 185 
serum ALP activity was measured in 99 (58.9%) dogs before surgery and was greater 186 
than the reference range in 22 (22.2%) dogs. Monocyte and lymphocyte values were 187 
recorded for 98 (58.3%) dogs: 11 (11.2%) dogs had monocytosis and 1 (0.6%) had 188 
lymphocytosis. 189 
None had evidence of intra-thoracic and abdominal metastasis prior to treatment; 89 190 
(52.9%) dogs were staged by means of TBCT, whereas 79 (47.1%) underwent 3-view 191 
thoracic radiographs and abdominal ultrasound.  192 
Cytologic sampling of the regional lymph node was performed in 70 (41.7%) dogs, 193 
whereas histopathological evaluation of the excised lymph node was carried out in 98 194 
(58.3%) dogs. Overall, 7 (4.2%) dogs had histologically-confirmed regional lymph node 195 
metastasis. 196 
 197 
Treatment and side effects 198 
Osteosarcoma was removed surgically via coxofemoral disarticulation (n=66; 39.3%), 199 
forequarter amputation (n= 57; 33.9%), scapulohumeral joint disarticulation (n=32; 200 
19%), and hemipelvectomy in conjunction with pelvic limb amputation (n=13; 7.7%).  201 
Overall, 45 (26.8%) dogs experienced surgical complications: 38 were classified as 202 
minor and 7 as major. Among the minor complications, the following were reported: 203 
seroma (n=24), hematoma (n=4), mild wound infection (n=4), edema (n=2), partial 204 
suture dehiscence (n=1), tracheitis (n=1), external otitis due to wearing E-collar (n=1), 205 
and contralateral muscle injury (n=1). Among the major complications, there were 206 
wound dehiscence requiring second surgery (n=2), phantom limb syndrome (n=1), 207 
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disseminated intravascular coagulopathy (n=1), soft tissue necrosis requiring second 208 
surgery (n=1), E. coli infection requiring second surgery (n=1), and life threatening 209 
bleeding from the surgery site (n=1). All dogs with surgical complications recovered 210 
fully. 211 
 212 
All dogs received intravenous chemotherapy: 107 (63.7%) received single-agent 213 
carboplatin (median 4; range, 2 to 6), 12 (7.1%) received single-agent doxorubicin 214 
(median, 4; range, 3 to 5), 11 (6.5%) received single-agent cisplatin (median, 3; range 3 215 
to 4), 33 (19.6%) received alternating doses of a platinum compound (25 cisplatin, 8 216 
carboplatin) and doxorubicin (median, 4; range, 2 to 8), 4 (2.4%) received combined 217 
doses of cisplatin and dacarbazine (median, 4; range 4 to 6), and 1 (0.6%) dog received 218 
alternating doses of carboplatin and epirubicin (3 cycles each). 219 
Carboplatin was given at a median dose of 300 mg/m2 (range, 210 to 300 mg/m2), 220 
doxorubicin at a median dose of 30 mg/m2 (range, 15 to 30 mg/m2), cisplatin at a 221 
median dose of 70 mg/m2 (range, 60 to 70 mg/m2), dacarbazine was administered at 200 222 
mg/m2 for 5 consecutive days in all dogs, and epirubicin was given at 30 mg/m2. 223 
Toxicity data were available for 156 (92.9%) dogs: among them, 56 (35.8%) 224 
experienced adverse events. Overall, there were 40 episodes of bone marrow toxicity 225 
(n=27 grade 1, n=6 grade 2, n=5 grade 3, n=2 grade 4), 17 episodes of gastro-intestinal 226 
toxicity (n=7 grade 1, n=9 grade 2, n=1 grade 3), 3 episodes of grade 1 lethargy, and 1 227 
episode of grade 2 renal toxicity.  228 
Overall, 8 (14.3% of cases experiencing side effects, and 5.1% of the total cases) dogs 229 
had grade 3-4 toxicity. Two dogs with grade 4 bone marrow toxicity required dose 230 




In the whole study population, 148 dogs died and 20 were still alive at data analysis 234 
closure (median follow-up time, 323 days; range, 115 to 1196 days). Among the dogs 235 
that died, 135 (91.2%) succumbed to tumor-related causes. The 1-, 2-, and 3-year 236 
survival rate were 38%, 12% and 6%, respectively. The median TTP was 230 days 237 
(95% CI, 178-282). The median OS was 278 days (95% CI, 226-330). 238 
 239 
Time interval between surgery and chemotherapy and analysis of prognostic factors 240 
The median TI was 14 days (range, 1 to 210 days). In particular, 40 dogs were treated 241 
within the first 3 days from surgery, 52 within 5 days, 61 within 7 days, 69 within 10 242 
days, 99 within 15 days, 127 within 20 days, 152 within 30 days and the remaining 16 243 
after 30 days.  244 
Dogs experiencing no surgical complications received adjuvant chemotherapy at a 245 
median of 10 days (range, 1 to 210 days). Dogs experiencing minor surgical 246 
complications received adjuvant chemotherapy at a median of 16 days (range, 2 to 49 247 
days) versus a median of 28 days (range, 24 to 41 days) for those experiencing major 248 
complications. In dogs with major postoperative complications, the administration of 249 
adjuvant chemotherapy was significantly delayed (P < 0.001). 250 
Among dogs with no surgical complications, 10 (8%) had a delay of > 30 days in the 251 
start of chemotherapy. 252 
Dogs alive at 1 year following surgery received chemotherapy significantly earlier 253 
(median, 6 days) than dogs dying before 1 year (median, 14 days; P = 0.004). 254 
The TI associated with the best survival benefit was 5 days. Median TTP of dogs 255 
receiving chemotherapy within 5 days [375 days (95%CI, 162-588)] was longer than 256 
that of dogs being treated after 5 days [202 days (95%CI, 146-257)] and this difference 257 
was significant (P = 0.005; Figure 1; Table 1). 258 
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Median OS of dogs receiving chemotherapy within 5 days [445 days (95%CI, 345-259 
545)] was longer than that of dogs being treated after 5 days [239 days (95%CI, 187-260 
291)] and this difference was significant (P = 0.003; Figure 2; Table 1). Dogs receiving 261 
chemotherapy after 5 days from surgery had a 1.7-fold increase in risk of both tumor 262 
progression (95% CI, 1.2-2.4; P = 0.005) and death (95% CI, 1.2-2.5; P = 0.003; Table 263 
2). 264 
In dogs receiving chemotherapy within 5 days, the 1 year- (58% vs 29%) and 2 year- 265 
(20% vs 8%) survival rates were significantly higher (P < 0.001 and P = 0.028, 266 
respectively), whereas the 3 year- survival rate (12 vs 4%%) was not significantly 267 
different (Table 1). 268 
In the 16 dogs receiving chemotherapy greater than 30 days after amputation, median 269 
TTP and OS were 136 and 169 days, respectively. 270 
A long symptom duration was the only other variable significantly associated with an 271 
increased risk of tumor progression, whereas age greater than 5 years was associated 272 
with an increased risk of death (Table 2). On multivariable analysis, TI > 5 days and 273 
symptom duration > 28 days were significantly associated with an increased risk of 274 
tumor progression, while TI was the only variable retaining prognostic significance for 275 
overall survival (Tables 3 and 4). 276 
When examining all the potential prognostic variables separately among dogs receiving 277 
chemotherapy within or after 5 days from surgery, the two groups were well balanced 278 
with the exception of weight (lower proportion of dogs > 32 kg in the early 279 
chemotherapy group; 36% vs. 57%; P = 0.015), staging (lower proportion of dogs 280 
undergoing TBCT in the early chemotherapy group; 28% vs. 64%;  P <0.001) and 281 
number of subjects experiencing chemotherapy-related toxicity (significantly lower in 282 






While the benefit of adjuvant chemotherapy to dogs with resected osteosarcoma has 288 
been documented, optimal timing after limb amputation has never been defined.  289 
In the current retrospective study, it was shown that there was a statistically significant 290 
association with longer survival for earlier delivery of chemotherapy in the adjuvant 291 
setting for dogs with appendicular osteosarcoma without distant metastases at 292 
presentation. The clearest statistical difference between patient groups was seen when 293 
comparing dogs with TI of 5 days or less with those with a TI of greater than 5 days. 294 
The median survival times were 445 days and 239 days, respectively. 295 
There are several possible biological reasons behind these findings. 296 
The ultimate goal of adjuvant chemotherapy is to decrease the chance of metastatic 297 
development by eradicating neoplastic cells after surgery.  298 
According to the mathematic model by Goldie and Coldman,15 drug sensitivity of 299 
neoplastic cells is related to their spontaneous mutation rate toward a drug-resistant 300 
phenotype; because tumor mutation rate increases over time, a longer TI between 301 
surgery and onset of chemotherapy may increase the occurrence of a chemo-resistant 302 
phenotype.  303 
Also, a long TI may facilitate the proliferation of residual malignant cells. This has been 304 
documented by murine studies in which the surgical removal of the primary tumor led 305 
to an increase in the number of circulating tumor cells, thereby accelerating the 306 
progression of the micrometastatic burden.6 According to other studies, primary tumor 307 
removal accelerates angiogenesis by releasing oncogenic growth factors and is 308 
permissive of tumor growth through inducing immunosuppression.16-20 Due to the 309 
above, chemotherapy is believed to be more effective if initiated when the tumor burden 310 
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is low and when cancer cells are multiplying most rapidly. 311 
This being said, it must be noted that while the 1- and 2-year survival rate was 312 
significantly higher in those dogs receiving early rather than delayed chemotherapy, the 313 
advantage was lost at 3 years. Surviving cases were too few for meaningful 314 
comparisons at this point, so the result should be regarded with caution, but if this loss 315 
of a differential effect of TI is real, this simply highlights that osteosarcoma remains a 316 
largely incurable disease for which new treatment strategies are greatly needed. 317 
It has been argued that perioperative chemotherapy-induced toxicity may be maximized 318 
due to immunodepression after surgery; therefore, a short TI may cause severe adverse 319 
events.21 In the current study, the initiation of adjuvant chemotherapy within 5 days 320 
after surgery was feasible, with no increase in incidence of grade 3 or 4 toxicity. 321 
A further unanswered question is whether there is an ideal timing for adjuvant 322 
chemotherapy after which treatment benefit decreases. 323 
In the current study, dogs receiving chemotherapy after 30 days had a median TTP and 324 
OS of 136 and 169 days, respectively. For amputation alone, a median survival time of 325 
119-175 days has been previously reported, with the majority of dogs being euthanized 326 
because of metastatic disease.13,22,23 A crude comparison shows that the survival benefit 327 
of adjuvant chemotherapy is almost lost with a delay of approximately 4 weeks from 328 
amputation, and it is questionable whether systemic treatment is appropriate after this 329 
time. 330 
That the survival benefit of adjuvant chemotherapy is time-dependent is not new. 331 
As stated above, Goldie et al.24 suggested that the drug sensitivity of a tumor is related 332 
to the spontaneous mutation rate toward phenotypic drug resistance, which is a function 333 
of time. Furthermore, according to the mathematical model by Harless,25 the 334 
effectiveness of chemotherapy is inversely proportional to the tumor burden that had to 335 
be eradicated, which, in turn, is a function of the interval to initiation of chemotherapy 336 
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after surgery.  337 
In people with high-grade appendicular osteosarcoma, neoadjuvant chemotherapy 338 
followed by surgery and adjuvant chemotherapy is the most-frequently employed 339 
strategy. Neoadjuvant chemotherapy is aimed at treating micrometastatic disease early, 340 
thereby reducing the risk of distant metastasis, and provides an indication of tumor 341 
responsiveness to chemotherapy.26 342 
In dogs, chemotherapy did not significantly increase survival time when started 343 
preoperatively or intraoperatively;13,22,23 nevertheless, this has not been addressed in 344 
prospective studies and merits further investigation.  345 
In multivariate analysis, a long symptom duration was also significantly associated with 346 
an increased risk of tumor progression. This was not unexpected, as dogs that had 347 
experienced clinical signs for longer were more likely to have had time for 348 
micrometastases to establish a niche at distant sites and therefore of to progress sooner.  349 
 350 
Our findings need to be interpreted in the context of the study’s strengths and 351 
limitations. While every effort was made to reduce any selection bias, due to the 352 
retrospective nature of the study some information was not retrieved from the medical 353 
records, including ALP, lymphocyte and monocyte count.  354 
Dogs were included only if they received at least 2 cycles of chemotherapy as the 355 
response to only one cycle would have been difficult to evaluate, given that the first 356 
restaging by means of imaging was suggested after 2-3 courses of chemotherapy.  357 
In the current study, approximately 50% of dogs were worked-up by means of thoracic 358 
radiographs and abdominal ultrasound, which may have potentially underestimated their 359 
stage. However, the choice of imaging technique did not appear to affect tumor 360 
progression or mortality in our series. Furthermore, when considering the 5-days TI 361 
window, only 28% of dogs underwent TBCT versus 64% of dogs receiving 362 
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chemotherapy at a later timepoint, and this difference was significant. Since the 363 
resolution of CT is superior for the detection of metastasis, this observation serves to 364 
reinforce the finding of an improved survival following a short TI.  365 
Although restaging with thoracic radiographs was recommended every 2-3 cycles of 366 
chemotherapy for all dogs, the actual frequency of restaging was variable; the lack of 367 
standardization may have overestimated TTP. 368 
Also, even though all dogs underwent cytological evaluation of the regional lymph 369 
nodes, only 60% of them had a histopathological evaluation, therefore the true 370 
prevalence of lymph node metastasis may have been underestimated. 371 
Similarly, slides were not reviewed, and histological grade and osteosarcoma subtypes 372 
were not available for the majority of dogs, possibly impacting outcome. 373 
Why dogs experienced delayed chemotherapy administration was not completely 374 
addressed in the current study. Various causes may be responsible for the long TI, 375 
including delay in referral, surgical complications, logistical issues, oncologists’ and/or 376 
owners’ choice.  377 
Overall, 45 (26.8%) dogs had some form of surgical complications, either minor (n=38) 378 
or major (n=7). The observation that 8 of these dogs had a delay in the start of 379 
chemotherapy of more than 30 days was not unexpected, because animals with 380 
postoperative complications were likely to require more time for recovery, but what it is 381 
most surprising is that 8% of the dogs with no reported complications still had a delay 382 
of more than 30 days. Although the reasons behind this were not investigated, some 383 
hypothesis can be made, including delay to obtain the histopathological diagnosis due to 384 
sample decalcifying or delay to refer to an oncologist after diagnosis. 385 
We also found that the risk of chemotherapy-related adverse events was not increased to 386 
the same extent as the risk of death in the group with delayed start of chemotherapy. 387 
 16 
Multidisciplinary treatment strategies are needed to reduce postoperative complications 388 
and promote timely adjuvant chemotherapy.27  389 
Various chemotherapy protocols have been used in the current study; however, previous 390 
publications have identified similar outcomes regardless of protocols, number of cycles 391 
and intertreatment interval.3,10  392 
Last, the lack of necropsy data and standardized diagnostics to determine cause of death 393 
may have affected our outcome data. 394 
Despite the potential flaws in the accuracy of the information collected, we do not feel 395 
that these shortcomings invalidate the conclusions of the study.  396 
 397 
Our findings support the view that starting adjuvant chemotherapy within 5 days post-398 
surgery is associated with a significant survival benefit in dogs with non-metastatic 399 
appendicular osteosarcoma. These results suggest that the timing of chemotherapy 400 
initiation is an important variable and that great efforts should be made to minimize 401 
post-surgical recovery time. Besides, given the lack of impact on treatment-related 402 
toxicity, adjuvant chemotherapy should probably be anticipated, in accordance with 403 
patient’s condition, at the earliest possible time, following the human model. We hope 404 
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Figure legends 487 
Figure 1. Time to progression curves for 168 dogs with appendicular osteosarcoma treated 488 
with adjuvant chemotherapy within or after 5 days from limb amputation. In the early 489 
chemotherapy group, dogs had a significantly longer time to progression (375 vs 202 days; P 490 
= 0.005). 491 
Figure 2. Overall survival curves for 168 dogs with appendicular osteosarcoma treated with 492 
adjuvant chemotherapy within or after 5 days from limb amputation. In the early 493 
chemotherapy group, dogs had a significantly longer time to progression (445 vs 239 days; P 494 




Table 1. Baseline characteristics and survival analysis of 168 dogs with appendicular 499 
osteosarcoma treated with adjuvant chemotherapy within or after 5 days from limb 500 
amputation. 501 
Variables TI ≤ 5 days 
(n = 52) 
TI > 5 days 
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≤ 32 kg 







































































































yes 8 48 










Median TTP (95% CI) 375 (162-588) 202 (146-
257) 
0.005* 
Median OS (95% CI) 445 (345-545) 239 (187-
291) 
0.003* 
1 year-survival rate 29/50 (58.0%) 31/108 
(28.7%) 
<0.001* 
2 year-survival rate 9/44 (20.4%) 8/107 (7.5%) 0.028* 
3 year-survival rate 5/43 (11.6%) 4/106 (3.8%) 0.121 
Abbreviations: TI, time interval between amputation and chemotherapy; TTP, time to 502 
progression; OS, overall survival; 3 RX, 3-view thoracic radiographs; ABDO US, 503 
abdominal ultrasound; TBCT, total body computed tomography; CI, confidence 504 
interval. 505 
* = significant; a = median used as cutoff value; b = data not available for all dogs. 506 
 507 
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 509 
Table 2. Univariable Cox regression analysis of variables potentially associated with 510 
increased risk of tumour progression and mortality in 168 dogs with appendicular 511 

















≤ 5 years 
> 5 yearsa 




≤ 32 kg 
> 32 kga 




≤ 28 days 
> 28 daysa 












1.1 (0.7-1.8) 0.659 1.1 (0.7-
1.8) 
0.663 







3 RX + ABDO USa 
1.1 (0.8-1.5) 0.595 1.1 (0.8-
1.6) 
0.410 

















0.8 (0.6-1.2) 0.391 0.9 (0.6-
1.2) 
0.407 
Grades 3 and 4 toxicityc 
no 
yesa 
0.6 (0.3-1.2) 0.129 0.5 (0.2-
1.1) 
0.086 
Time interval between 
amputation and 
chemotherapy 
≤ 5 days 
> 5 daysa 
1.7 (1.2-2.4) 0.005* 1.7 (1.2-
2.5) 
0.003* 
Abbreviations: HR, hazard ratio; CI, confidence interval; 3 RX, 3-view thoracic 513 
radiographs; ABDO US, abdominal ultrasound; TBCT, total body computed 514 
tomography. 515 
 25 
* = significant; a = reference category; b = median used as cutoff value; c = data not 516 
available for all dogs. 517 
 518 
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 520 
Table 3. Multivariable Cox regression analysis of variables potentially associated with 521 
increased risk of tumor progression in 168 dogs with appendicular osteosarcoma treated 522 
with amputation and adjuvant chemotherapy. 523 
Variable Tumor progression 
HR (95% CI) 
P 
Symptom duration > 28 days 2.8 (1.4-5.4) 0.002* 
Time interval between amputation and 
chemotherapy > 5 days 
1.6 (1.0-2.3) 0.027* 
Abbreviations: HR, hazard ratio; CI, confidence interval. 524 
* = significant. 525 
 526 
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 528 
Table 4. Multivariable Cox regression analysis of variables potentially associated with 529 
increased risk of mortality in 168 dogs with appendicular osteosarcoma treated with 530 
amputation and adjuvant chemotherapy. 531 
Variable Mortality 
HR (95% CI) 
P 
Age > 5 years 1.1 (0.5-2.6) 0.721 
Symptom duration > 28 days 1.5 (0.9-2.2) 0.069 
Time interval between amputation and 
chemotherapy > 5 days 
2.3 (1.2-4.5) 0.011* 
Grades 3 and 4 toxicity 1.1 (0.5-2.6) 0.721 
Abbreviations: HR, hazard ratio; CI, confidence interval. 532 
* = significant. 533 
 534 
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